531 results about "Biological drugs" patented technology

Significant research is being done to develop and improve delivery mechanisms for biopharmaceuticals and vaccines, including pulmonary (inhalation), nasal, transdermal, and oral alternatives. Market projections indicate that the delivery of proteins and vaccines by inhalation and oral formulation has become and will continue to be increasingly important. These delivery mechanisms, to be effective, will require better stabilization of the biologicals so that they can maintain potency and effectiveness at ambient temperatures for extended periods of time. The novel Preservation by Vaporization (PBV) Technology described herein provides cost-effective and efficient industrial scale stabilization of proteins, viruses, bacteria, and other sensitive biologicals, thereby allowing a production of products that are not possible to be produced by existing methods. The suggested new PBV process comprises primary drying under vacuum from a partially frozen state (i.e. slush) at near subzero temperatures followed by stability drying at elevated temperatures (i.e., above 40 degrees Celsius). The new suggested method can be performed aseptically in unit doze format (in vials) and/or in bulk format (in trays, bags, or other containers). The drying can be performed as a continuous load process in a manifold vacuum dryer comprising a plurality (e.g., 30) of vacuum chambers attached to a condenser during the drying.

New compositions formed from the combination of an active substance with a hydrogel carrier moiety are provided. The compositions are suitable for use in high-velocity transdermal particle injection techniques. Methods of providing the new compositions are also provided. In addition, methods for administering pharmacologically active agent to a subject are provided. These methods are useful for delivering drugs, biopharmaceuticals, vaccines and diagnostics agents.

The present invention is directed to the development of continuous processing technology for the purification of biopharmaceuticals and biological products, such as monoclonal antibodies, protein therapeutics, and vaccines. Methods for continuous processing of a biological product in a feed stream toward formulation of a purified bulk product are described.

The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R¹, R² and R³ are as defined herein. The present invention also relates to compositions comprising at least one 2′-Azido Substituted Nucleoside Derivative, and methods of using the 2′-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

The present invention discloses an active biological drug fertilizer, which is characterized in that: the present invention is prepared with the fermenting process by photosynthetic bacteria, yellow corrupted acid and the extraction from Azadirachtin, Langdu Root and kusnezoff monkshood. The present invention is with an especial function for killing insect and preventing disease as well as accelerating the growth for the plant, protecting flower and fruit, enhancing the output and improving the integrative performance for the product quality and so on. The present invention is adaptable to the crops including rice, wheat, cotton, cole, bean, earthpea, corn, bast fibre plants, watermelon, fruit tree, vegetable, tobacco leaf, tea leaf, medicinal materials, flower, and pasture and seeding wood and so on. Besides, the present invention has also the function for accelerating the output for the pecan. The prevention and cure objects include: lepidopterans, orthopteran, Diptera, Coleoptera, ring vein, Hymenoptera and acarid and so on. The present invention has the much higher sensitivity to the following pests including: prodenia litura, asparagus caterpillar, cabbage butterfly, tea geometrid, tea smaller green leaf hopper, pecan peachblossom maggot and locust and so on.

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative,and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.

The present invention relates to 2′-Cyano Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R¹, R² and R³ are as defined herein. The present invention also relates to compositions comprising at least one 2′-Cyano Substituted Nucleoside Derivative, and methods of using the 2′-Cyano Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

The invention proposes a biological drug for organic vegetables for preventing plant diseases and insect pests, wherein the biological drug comprises the following components by weight: main ingredients, including 3-6kg of radishes, 3-6kg of onions, 3-6kg of garlic, 3-6kg of hot pepper, 3-6kg of pepper and 3-6kg of pine needles, 8-12kg of plant ashes, auxiliary ingredients, including 3-5kg of cacumen biotae, 3-5kg of quispualis indica, 3-5kg of fructus cnidii, 3-5kg of fructus kochiae, 3-5kg of aloes, 3-5kg of rheum officinale, 3-5kg of white alum, 3-5kg of stone-like omphalia, 3-5kg of radix stemonae, 3-5kg of ginger and 3-5kg of cinnamon, and assistants, including 8-12kg of 10% soduim chloride water solution, 8-12kg of 10% magnesium chloride water solution and 8-12kg of 8% sodium carboxymethylcellulose water solution. The biological drug is simple in proportioning, and convenient to use, and a plurality of plant diseases and insect pests can be effectively prevented and treated.

The invention discloses a method for preparing nano-porous light silicon oxide microspheres. The nano-porous light silicon oxide microspheres are prepared by adding a surfactant to form an emulsion system and carrying out chemical reaction by mainly adopting water glass as a precursor, a solvent with a low surface tension as a replacement solvent and an organic silane compound as a hydrophobic modifier in the presence of inorganic acid as a catalyst. The method for preparing the nano-porous light silicon oxide microspheres is simple in process flow; in addition, the production raw materials are low in price, the solvent is easy to recover, and low production cost and high yield are achieved; in the preparation process adopted in the invention, no cation exchange resin is needed in the ion-exchange process, so that large-scale industrial production is facilitated; and the nano-porous light silicon oxide microspheres prepared by the method are of a typical nano-porous structure and can be applied to the fields, such as thermal insulation, chromatographic separation, catalysis and biological drug loading.

The invention discloses a method and a system for discovering and integrating rectal cancer related genes by utilizing public data resources and analyzing functions of the rectal cancer related genes, and an application. Based on the public data resources, open big data resources and diversified bioinformatics analysis means are reasonably used for performing analysis processing on mRNA expression data, and important genes related to complex diseases and functions of the important genes are identified. The method comprises the steps of sample data downloading and management; gene expression data analysis; difference expression gene screening; and gene function analysis and protein interaction analysis. According to the method and the system, the problems of weakness in integrating existing network resources, unfamiliarity with mRNA related most common databases and frontal analysis methods, incapability of independently finishing mRNA expression spectrum related bioinformatics analysis and the like can be solved; a plurality of risk pathways and genes related to the complex diseases such as the rectal cancer and the like can be discovered; and the method and the system are of important significance for biological targeted treatment of the complex diseases, biological drug research and development, pathogenesis explanation and risk prediction.

A sterile, closed, disposable system for formulating biopharmaceutical compositions containing multiple active agents is described herein.

Disclosed are guanidine and biguanidine derivatives which have anti-viral and antibacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds. Methods of treating infections using the guanidine and biguanidine derivatives are also disclosed.

The invention provides fowlpox virus vector shuttle plasmid pTGP3 which comprises recombinant arms TKL and TKR, a bidirectional promoter PE/L, a fluorescent protein expression cassette, and a resistant marker gene and replication origin ori; the upstream and the downstream of the bidirectional promoter PE/L are respectively provided with cloning sites MCSL and MCSR; and both ends of the fluorescent protein expression cassette are provided with loxp sequences. The plasmid of the invention has two different screening markers, and the recombinant fowlpox virus prepared with the plasmid can express 1 to 3 types of gene with different meshes in the whole processes of the early and the later periods; the strong composite promoter with expression activity in the early and the later periods is applied so as to realize the all-process high-efficiency expression of a target gene; and the loxp sequences are introduced into both ends of the fluorescent protein expression cassette, so as to knock out the exogenous recombinant fowlpox virus screening markers. The invention lays foundation for the series and the scale application of the recombinant fowlpox virus in vaccine and biological drug research and development fields.

The present invention relates to a particle stabilized emulsion or foam comprising at least two phases and solid particles, wherein said solid particles are starch granules and said starch granules or a portion thereof are situated at the interface between the two phases providing the particle stabilized emulsion or foam. The invention further relates to the use of said particle stabilized emulsion or foam for encapsulation of substances chosen from biopharmaceuticals, proteins, probiotics, living cells, enzymes and antibodies, sensitive food ingredients, vitamins, and lipids in food products, cosmetic products, skin creams, and pharmaceutical formulations.

The invention discloses a method for de-agglomerating a nano diamond, and particularly relates to a method for preparing nano diamond hydrosol. Due to a ball-milling mode, under the condition without any additive, stably dispersed nano diamond hydrosol is obtained; the method comprises the following technical processes: acidizing nano diamond raw powder, adding a certain amount of ball-milling beads and deionized water to carry out wet ball-milling; carrying out ultrasonic dispersion on the obtained nano diamond suspension and ball-milling beads; and finally standing and centrifugally processing the obtained suspension to remove impurities and large particles, so as to obtain nano diamond hydrosol of about 10nm. The hydrosol prepared by the method can be applied to the field of precision polishing; and with respect to agglomerated large-grained nano diamond, the nano diamond hydrosol has higher polishing accuracy, can be applied to mechanical performance enhancement application of composite materials as an additive, and simultaneously can also be applied to research of the field of biological drug transportation.

The present invention relates to the field of biopharmaceuticals, and in particular to a glucagon analog for treating metabolic diseases. The structural formula is: H-X2-X3-GTFTSD-X10-SKYLD-X16-X17-AAQ-DFVQWLMN-X29-X<z> or H-S-Q-GTFTSD-Y-SKYLD-X16-X17-AAQ-DFVQWLMN-X29-Xz-NH2. The described glucagon analogue has a GLP-1/GCG/GIP triple receptor agonist activity and better enzyme resistant stabilityfor neutral endopeptidase (NEP) and dipeptidyl peptidase-4(DPP-4), and has a longer half-life in vivo and duration of action compared with natural glucagon, GLP-1 and GIP.

Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant/antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and/or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.